AcelRx releases results of SAP303 trial

AcelRx released the results of its SAP303 trial through a conference call and webcast.
AcelRx released the results of its SAP303 trial through a conference call and webcast. | shutterstock
AcelRx Pharmaceuticals Inc. announced the release of the results of its Phase 3 ARX-04 trial during a conference call and through a webcast on Sept. 15.

The trial, which is called SAP303, was conducted across multiple centers and was open-label. It involved patients who have moderate-to-severe acute pain after the completion of a surgical procedure. Patients involved in the study are 40 years of age or older.

The conference call and webcast were held at 9 a.m. EST with AcelRx sharing the results of the SAP303 trial. The conference call was available to anyone who wished to participate in the United States, Canada and all over the world. It could also be heard online, where a link was also posted to view the webcast. The replay of the webcast is available for 90 days at www.acelrx.com.

Want to get notified whenever we write about AcelRx Pharmaceuticals, Inc. ?
Next time we write about AcelRx Pharmaceuticals, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

AcelRx Pharmaceuticals, Inc. 351 Galveston Dr Redwood City, CA 94063